Our study is aimed to evaluate the efficacy and safety of novel ADC named SHR-A1921 combined with Adebrelimab in endocrine therapy-failed HR (Hormone Receptor)-positive, HER2-negative advanced breast cancer.
18 years to 75 years old, female patients with breast cancer;
ECOG PS Score: 0~1;
Histologically or cytologically confirmed HR-positive, HER2-negative advanced or metastatic breast cancer;
PD-L1 positive;
Has leptomeningeal metastasis confirmed by MRI or lumbar puncture;
Has CNS metastasis confirmed by radiology, except following conditions: ①asymptomatic brain metastasis that is not required to radiotherapy or surgery immediately; ②prior local therapy (e.g. radiotherapy or surgery) for brain or dural metastasis, of which stable disease lasting at least 4 weeks confirmed by radiography, and symptomatic therapy (e.g. hormone, mannitol, bevacizumab) has been stopped beyond 2 weeks with no clinical symptom;
Prior anti-TROP-2 treatment;
Has received or been receiving PD-(L)1 inhibitors and/or ADC containing a topoisomerase inhibitor-like payload;